Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Liposomal nanomedicines.

David B Fenske1, Pieter R Cullis

  • 1Department of Chemistry, University College of the Fraser Valley, 33844 King Road, Abbotsford, BC, V2S 7M8, Canada. david.fenske@ucfv.ca

Expert Opinion on Drug Delivery
|December 22, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Liposomal lipid nanoparticles containing dihydrosphingomyelin exhibit improved stability and extended hepatic and extrahepatic transfection.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same author

Direct Counting of mRNA Copies Inside Individual Lipid Nanoparticles Using In Situ Lysis and Labeling.

Analytical chemistry·2026
Same author

Hybrid Lipid Nanoparticles Containing Iron Oxide Nanoparticles and Doxorubicin.

Langmuir : the ACS journal of surfaces and colloids·2026
Same author

Silencing of PAI-1 using siRNA-lipid nanoparticles reduces thrombosis and prolongs life span in murine models.

Blood·2026
Same author

Single-Particle Multiparametric Microscopy Reveals Structural, Size, and Payload Heterogeneity in mRNA-Loaded Lipid Nanoparticles.

ACS nano·2025
Same author

Lipid nanoparticle mediated base editing of the Q344X rhodopsin mutation associated with retinitis pigmentosa.

Gene therapy·2025
Same journal

Dry powder inhaler selection in COPD: integrating device design, formulation performance, and patient inspiratory capability.

Expert opinion on drug delivery·2026
Same journal

Letter to the Editor: 'saving money but costing lives: the lack of integrated dose counters on pressurised metered dose inhalers'.

Expert opinion on drug delivery·2026
Same journal

Response to letter to the editor: 'Saving money but costing lives: the lack of integrated dose counters on pressurised metered dose inhalers'.

Expert opinion on drug delivery·2026
Same journal

Mechanism-guided metal complex therapeutics for biofilm-driven wound infections and transdermal delivery.

Expert opinion on drug delivery·2026
Same journal

Next-generation strategies for PROTAC formulation: mechanistic insights and advanced formulation technologies.

Expert opinion on drug delivery·2026
Same journal

Drug penetration in solid tumors: influence of drug size and capillary architecture.

Expert opinion on drug delivery·2026
See all related articles

Liposomal nanoparticles (LNs) offer advanced drug delivery for cancer and genetic therapies. These nanomedicines accumulate at disease sites, improving treatment efficacy and reducing side effects.

Area of Science:

  • Nanomedicine
  • Drug Delivery Systems
  • Biotechnology

Background:

  • Liposomal nanoparticles (LNs) are advanced drug delivery systems with existing market formulations and ongoing clinical trials.
  • Techniques have evolved to encapsulate both conventional drugs (anticancer, antibiotics) and genetic materials (DNA, siRNA) within LNs.
  • LNs with specific properties ( 100 nm diameter, high drug retention, long circulation) accumulate at disease sites like tumors.

Purpose of the Study:

  • To review recent advancements in liposomal nanomedicines.
  • To highlight applications in cancer therapy, gene delivery, and immune system modulation.
  • To discuss the potential of LNs for new therapeutic strategies.

Main Methods:

  • Review of scientific literature on liposomal nanoparticle formulation and application.

Related Experiment Videos

  • Analysis of properties enabling targeted drug delivery and accumulation at disease sites.
  • Discussion of encapsulation techniques for diverse therapeutic agents.

    • Main Results:

    • Liposomal nanomedicines demonstrate effective encapsulation of anticancer and genetic drugs.
    • Specific LN properties facilitate accumulation in diseased tissues, such as tumors.
    • LNs protect therapeutic payloads and minimize exposure to healthy tissues.

    Conclusions:

    • Liposomal nanomedicines represent a promising platform for advanced therapeutics.
    • Potential applications span cancer treatment, vaccine development, and cholesterol management.
    • Continued research in LN technology is expected to yield novel therapeutic solutions.